
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is projecting annual sales of its primary product, Korlym, to grow between 19% and 26% year-over-year, indicating strong underlying demand and the company’s ability to navigate recent commercial challenges. The positive clinical trial results for relacorilant in combination with nab-paclitaxel demonstrate its potential to significantly benefit patients with advanced ovarian cancer, which could lead to expanded indications and market opportunities. Additionally, the anticipated favorable regulatory outcomes for relacorilant in treating hypercortisolism further enhance the company's growth prospects, positioning it for substantial market expansion in the coming years.
Bears say
Corcept Therapeutics Inc has revised its financial outlook significantly, lowering its 12-month price target from $145 to $90 per diluted share due to the recent Complete Response Letter (CRL) and anticipated delays in launching relacorilant for Cushing's Syndrome treatment. The company's stock experienced a notable decline, closing at approximately $35, reflecting a loss of -50.4%, which highlights market concerns regarding its revenue projections and commercial distribution changes. Given these developments and the uncertainty surrounding future earnings and sales growth, there are fundamental reasons for a negative outlook on the stock despite management's previous successes in drug launches.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares